Clinical Trials Browser

Phase 3 × First Line Metastatic Breast Cancer × Clear all

NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase 3 Terminated

First Line Metastatic Breast Cancer